306 related articles for article (PubMed ID: 6422861)
1. [Pharmacology and metabolism of a new therapeutic drug for prostatic cancer "Estracyt"].
Yamanaka H; Shida K
Gan To Kagaku Ryoho; 1984 Mar; 11(3):537-44. PubMed ID: 6422861
[TBL] [Abstract][Full Text] [Related]
2. [Estracyt (estradiol-nitrogen mustard complex)--estramustine binding protein and its specificity].
Yamanaka H; Imai K; Suzuki T; Yuasa H; Takahashi E
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2106-14. PubMed ID: 6486830
[TBL] [Abstract][Full Text] [Related]
3. Differential uptake of estramustine phosphate metabolites and its correlation with the levels of estramustine binding protein in prostate tumor tissue.
Walz PH; Björk P; Gunnarsson PO; Edman K; Hartley-Asp B
Clin Cancer Res; 1998 Sep; 4(9):2079-84. PubMed ID: 9748122
[TBL] [Abstract][Full Text] [Related]
4. Uptake of estramustine phosphate (estracyt) metabolites in prostatic cancer.
Norlén BJ; Andersson SB; Björk P; Gunnarsson PO; Fritjofsson A
J Urol; 1988 Nov; 140(5):1058-62. PubMed ID: 3172360
[TBL] [Abstract][Full Text] [Related]
5. The absorption metabolism, and excretion of Estracyt (NSC 89199) in patients with prostatic cancer.
Forshell GP; Müntzing J; Ek A; Lindstedt E; Dencker H
Invest Urol; 1976 Sep; 14(2):128-31. PubMed ID: 972005
[TBL] [Abstract][Full Text] [Related]
6. Partial characterization and "quantitation" of a human prostatic estramustine-binding protein.
Björk P; Forsgren B; Gustafsson JA; Pousette A; Högberg B
Cancer Res; 1982 May; 42(5):1935-42. PubMed ID: 7066904
[TBL] [Abstract][Full Text] [Related]
7. [Clinical effects of estramustine phosphate disodium (Estracyt) on prostatic cancer].
Nishio S; Kishimoto T; Maekawa M; Kawakita J; Hayahara N; Yuki K; Morikawa Y; Yasumoto R; Kato Y; Funai K
Hinyokika Kiyo; 1986 Nov; 32(11):1763-70. PubMed ID: 3825823
[TBL] [Abstract][Full Text] [Related]
8. [Clinical studies on serum lipids in the patients with tumor of the prostate gland. 2nd. Report. Changes of serum lipids and lipoprotein fractions during the treatment of estramustine phosphate disodium, hexestrol and diethylstilbestrol 4, 4-diphosphoric ester for the patients with prostatic cancer (author's transl)].
Yoshida H; Shimada M
Nihon Hinyokika Gakkai Zasshi; 1980 Jan; 71(1):59-69. PubMed ID: 6155501
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of retention of estramustine in the rat prostate and results of a clinical trial of Estracyt in Japan.
Yamanaka H; Imai K; Yuasa H; Shida K
Prostate; 1981; Suppl 1():95-102. PubMed ID: 7043423
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of 3H-thymidine and 14C-amino acids into the ventral prostate after in vivo treatment with estradiol-3N-BIS(2-chloroethyl)carbamate-17 beta-phosphate (Estracyt) and its estrogen and cytostatic parts.
Hoisaeter PA
Invest Urol; 1976 Sep; 14(2):85-92. PubMed ID: 972011
[TBL] [Abstract][Full Text] [Related]
11. Estramustine phosphate: plasma concentrations of its metabolites following oral administration to man, rat and dog.
Dixon R; Brooks M; Gill G
Res Commun Chem Pathol Pharmacol; 1980 Jan; 27(1):17-29. PubMed ID: 7360997
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients.
Gunnarsson PO; Andersson SB; Johansson SA; Nilsson T; Plym-Forshell G
Eur J Clin Pharmacol; 1984; 26(1):113-9. PubMed ID: 6714283
[TBL] [Abstract][Full Text] [Related]
13. Intracellular effects of estramustine (Estracyt/Emcyt).
Tew KD; Stearns ME
Prog Clin Biol Res; 1989; 303():169-75. PubMed ID: 2674983
[No Abstract] [Full Text] [Related]
14. Treatment of oral estramustine phosphate (Estracyt) in prostatic carcinoma: influences on lipid and carbohydrate metabolism.
Gustafson A; Persson B; Tisell LE; Wiklund O; Ohlson R
Invest Urol; 1977 Nov; 15(3):220-4. PubMed ID: 591268
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of estramustine phosphate (Estracyt) in patients with prostatic carcinoma.
Andersson SB; Gunnarsson PO; Nilsson T; Forshell GP
Eur J Drug Metab Pharmacokinet; 1981; 6(2):149-54. PubMed ID: 7274309
[TBL] [Abstract][Full Text] [Related]
16. The presence in rat and human prostate of proteins that bind steroid-cytostatic complexes.
Forsgren B; Björk P; Carlström K; Gustafsson JA; Pousette A; Högberg B
Prog Clin Biol Res; 1981; 75A():391-407. PubMed ID: 7339627
[TBL] [Abstract][Full Text] [Related]
17. Binding characteristics of a major protein in rat ventral prostate cytosol that interacts with estramustine, a nitrogen mustard derivative of 17 beta-estradiol.
Forsgren B; Gustafsson JA; Pousette A; Högberg B
Cancer Res; 1979 Dec; 39(12):5155-64. PubMed ID: 40694
[TBL] [Abstract][Full Text] [Related]
18. [Clinical study of estramustine phosphate disodium (Estracyt) on prostatic cancer--results of long-term therapy for 38 patients with prostatic cancer].
Asakawa M; Wada S; Hayahara N; Yayumoto R; Kishimoto T; Maekawa M; Morikawa Y; Kawakita J; Umeda M; Horii A
Hinyokika Kiyo; 1990 Nov; 36(11):1361-9. PubMed ID: 2288316
[TBL] [Abstract][Full Text] [Related]
19. Inhibition by estramustine phosphate on estradiol and androgen binding in benign and malignant prostate in humans.
Nilsson I; Liskowski L; Nilsson T
Urology; 1976 Aug; 8(2):118-21. PubMed ID: 60819
[TBL] [Abstract][Full Text] [Related]
20. [Estracyt treatment in prostatic neoplasms].
Sander S
Tidsskr Nor Laegeforen; 1976 Jan; 96(1):27-8. PubMed ID: 1257949
[No Abstract] [Full Text] [Related]
[Next] [New Search]
